Targeting β3-Adrenergic Receptors in the Heart: Selective Agonism and β-Blockade
View Full Paper
Ask AI
Bookmark
Share
Why the study?
Does targeting beta3-adrenergic receptors improve cardiac metabolism, function, and remodeling in heart failure?
Population
Patients with heart failure and preclinical models of cardiac disease
Design
Review
Key result
Targeting beta-3 adrenergic receptors represents a novel potential strategy to improve cardiac metabolism, function, and remodeling in heart failure.
Authors
Discussion
Loading...
Member takes
Overview
Should not alter current HF management; leaves open beta-3 targeting for prospective validation.
Structured PICO
Does targeting beta3-adrenergic receptors improve cardiac metabolism, function, and remodeling in heart failure?
P
Population
Patients with heart failure and preclinical models of cardiac disease (including ischemia/reperfusion injury and pressure overload)
I
Intervention
Targeting beta3-adrenergic receptors (selective agonism with agents like mirabegron or beta-blockers with beta3 agonistic activity like nebivolol)
Targeting beta3-adrenergic receptors represents a novel potential strategy to improve cardiac function and remodeling in heart failure, potentially mediating some of the cardioprotective effects of certain beta-blockers.
Limitations
- The specific signaling pathways associated with beta-blocker-dependent activation/inhibition of b3ARs require further investigation.
- The b3AR function in the heart is still poorly investigated.
Cite This Study
Cannavò et al. (2016) conducted a review in Heart failure. Beta-3 adrenergic receptor agonists and beta-blockers was evaluated. Targeting beta-3 adrenergic receptors represents a novel potential strategy to improve cardiac metabolism, function, and remodeling in heart failure.
View Full Paper
Ask AI
Bookmark
Share